Agoura Hills-based biotech firm Acelyrin Inc. agreed to merge with San Francisco-based Alumis Inc. in a deal valued at $320 ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Alumis and Acelyrin have announced a definitive merger agreement, which will result in an all-stock transaction.

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

Alumis Inc. will merge with a Southern California drug developer in a deal that extends the combined companies' cash into ...

Under the terms of the deal, ACELYRIN shareholders will receive 0.4274 shares of Alumis common stock for each share of ACELYRIN common stock. Once the deal closes, Alumis stockholders will own about ...

Alumis Inc. and ACELYRIN, Inc. have announced a definitive merger agreement in an all-stock transaction, allowing Alumis to leverage increased financial flexibility and an expanded late-stage ...

Alumis (ALMS) and Acelyrin (SLRN) announced a definitive merger agreement under which Alumis and Acelyrin will merge in an all-stock ...

Alumis (Nasdaq: ALMS) and Acelyrin (Nasdaq: SLRN) have agreed to merge in an all-stock deal, creating a late-stage ...

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction.